{"name":"Mandibular prognathia","alternate_symbols":[],"id":"18035","type":"Finding","attribute_content":[],"medgen_id":"C0399526","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000251\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000279\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000303\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000328\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002051\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004648\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004656\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0008514\",\"type\":\"secondary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0008312\"}","{\"db\":\"MeSH\",\"id\":\"D008313\"}","{\"db\":\"OMIM\",\"id\":\"176700\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2964\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000303\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Big lower jaw\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000303\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Big mandible\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000303\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Enlarged mandible\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000303\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Enlargement of mandible\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000303\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hyperplasia of lower jaw\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000303\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hypertrophy of lower jaw\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000303\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hypertrophy of mandible\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000303\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Increased projection of lower jaw\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000303\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Increased projection of mandible\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000303\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Increased size of lower jaw\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000303\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Increased size of mandible\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000303\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Large lower jaw\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000303\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Large mandible\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000303\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Lower jaw excess\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000303\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Lower jaw hyperplasia\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000303\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Macromandible\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000303\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Mandible prognathism\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000303\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Mandibular excess\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000303\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Mandibular hyperplasia\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000303\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Mandibular macrognathia\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000303\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Prognathia\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000303\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Prognathism\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000303\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Prominent chin\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000303\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Prominent jaw\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000303\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Prominent lower jaw\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000303\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Prominent mandible\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000303\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Relative mandibular prognathism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10319\",\"ref_field\":\"gard_id\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000303\",\"ref_field\":\"name\"}"],"gard_id":"10319","alternate_names":["Big lower jaw","Big mandible","Enlarged mandible","Enlargement of mandible","Habsburg jaw","Hapsburg jaw","Hyperplasia of lower jaw","Hypertrophy of lower jaw","Hypertrophy of mandible","Increased projection of lower jaw","Increased projection of mandible","Increased size of lower jaw","Increased size of mandible","Large lower jaw","Large mandible","Lower jaw excess","Lower jaw hyperplasia","Macromandible","Mandible prognathism","Mandibular excess","Mandibular hyperplasia","Mandibular macrognathia","Prognathia","Prognathism","Prominent chin","Prominent jaw","Prominent lower jaw","Prominent mandible","Relative mandibular prognathism"],"keywords":[]}
{"name":"Hypoglycemia, neonatal, simulating foetopathia diabetica","alternate_symbols":[],"id":"5301","type":"Disease","attribute_content":[],"symbol":"HIHGHH","medgen_id":"C3278384","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009416\"}","{\"db\":\"OMIM\",\"id\":\"240900\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"293964\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hypoglycemia%2C+neonatal%2C+simulating+foetopathia+diabetica/8611\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"240900\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["Hypoinsulinemic hypoglycemia and hemihypertrophy"],"keywords":[]}
{"name":"Frontal upsweep of hair","alternate_symbols":["CROWN"],"id":"22951","type":"Finding","attribute_content":[],"symbol":"COWLICK","medgen_id":"C1185616","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002236\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"139400\",\"type\":\"MIM\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002236\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Frontal Cowlick\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002236\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Upswept frontal hair\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002236\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Upswept frontal hair pattern\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002236\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Upswept frontal hairline\"}","{\"db\":\"OMIM\",\"id\":\"139400\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CROWN\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002236\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"139400\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["Frontal Cowlick","Hair whorl","Upswept frontal hair","Upswept frontal hair pattern","Upswept frontal hairline"],"keywords":[]}
{"name":"Kilquist syndrome","alternate_symbols":[],"id":"41330","type":"Disease","attribute_content":[],"symbol":"KILQS","medgen_id":"CN293532","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0033664\"}","{\"db\":\"OMIM\",\"id\":\"619080\",\"type\":\"MIM\"}","{\"db\":\"Undiagnosed Diseases Network,NIH\",\"id\":\"18c3fb5f-b11b-44db-a639-\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"619080\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"keywords":[]}
{"name":"Polydactyly, preaxial II","alternate_symbols":[],"id":"3510","type":"Disease","attribute_content":["{\"Attribute\":{\"@Type\":\"GARD id\",\"@integerValue\":\"4260\"},\"XRef\":{\"@DB\":\"Office of Rare Diseases\",\"@ID\":\"4260\"}}"],"symbol":"PPD2","medgen_id":"C1868114","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008270\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0008465\"}","{\"db\":\"OMIM\",\"id\":\"174500\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"183700\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2439\"}","{\"db\":\"Orphanet\",\"id\":\"2950\"}","{\"db\":\"Orphanet\",\"id\":\"93336\"}","{\"db\":\"OMIM\",\"id\":\"174500\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"POLYDACTYLY OF TRIPHALANGEAL THUMB\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Patterson+Stevenson+syndrome/5632\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Patterson Stevenson syndrome\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0008465\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Patterson-Stevenson-Fontaine syndrome\"}","{\"db\":\"OMIM\",\"id\":\"183700\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPLIT-FOOT DEFORMITY WITH MANDIBULOFACIAL DYSOSTOSIS\"}","{\"db\":\"OMIM\",\"id\":\"174500\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"TPT-PS SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"174500\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"TRIPHALANGEAL THUMB-POLYDACTYLY SYNDROME\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5289\",\"ref_field\":\"gard_id\"}","{\"db\":\"OMIM\",\"id\":\"174500\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"gard_id":"5289","alternate_names":["POLYDACTYLY OF TRIPHALANGEAL THUMB","Patterson Stevenson syndrome","Patterson-Stevenson-Fontaine syndrome","SPLIT-FOOT DEFORMITY WITH MANDIBULOFACIAL DYSOSTOSIS","Split-foot deformity with ectrodactyly and mandibulofacial dysostosis","TPT-PS SYNDROME","TRIPHALANGEAL THUMB-POLYDACTYLY SYNDROME"],"keywords":[]}
{"name":"Renal cell carcinoma, papillary, 1","content":"{\"Citation\":[{\"@Abbrev\":\"ACMG/NSGC, 2015\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25394175\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"KCRNC, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24319509\",\"@Source\":\"PubMed\"}}]}","alternate_symbols":[],"id":"15845","type":"Disease","attribute_content":[],"symbol":"RCCP1","medgen_id":"C1336839","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011797\",\"type\":\"primary\"}","{\"db\":\"MeSH\",\"id\":\"D002292\"}","{\"db\":\"OMIM\",\"id\":\"605074\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"47044\"}","{\"db\":\"OMIM\",\"id\":\"164860.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RENAL CELL CARCINOMA, PAPILLARY, 1, SOMATIC\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"13215\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Renal+cell+carcinoma%2C+papillary%2C+1/9214\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"605074\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"gard_id":"13215","alternate_names":["Kidney cancer","RENAL CELL CARCINOMA, PAPILLARY, 1, SOMATIC","Renal adenocarcinoma","Renal cell cancer","Renal cell carcinoma 1","Renal cell carcinoma, somatic"],"keywords":["Hereditary cancer syndrome","Neoplasm"]}
{"name":"Endometrial carcinoma","content":"{\"Citation\":[{\"@Abbrev\":\"SGO, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24905773\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ASCO, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24493721\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"AHRQ, 2013\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"Technology Assessment on Genetic Testing or Molecular Pathology Testing of Cancers with Unknown Primary Site to Determine Origin\"},\"URL\":{\"$\":\"https://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id90TA.pdf\"}}]}","alternate_symbols":[],"id":"1151","type":"Disease","attribute_content":[],"medgen_id":"C0476089","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0012114\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0002447\"}","{\"db\":\"OMIM\",\"id\":\"608089\",\"type\":\"MIM\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Endometrial+cancer/8312\",\"ref_field\":\"name\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0012114\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"254878006\",\"ref_field\":\"name\"}"],"alternate_names":["Endometrial cancer, somatic","Endometrial carcinoma, somatic"],"keywords":["Hereditary cancer syndrome"]}
{"name":"Pulmonary arteriovenous malformation","alternate_symbols":[],"id":"25670","type":"Disease","attribute_content":[],"symbol":"PAVM","medgen_id":"C1857690","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002114\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006537\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006548\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006548\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Pulmonary av malformation\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006548\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9777\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9777\",\"ref_field\":\"symbol\"}"],"alternate_names":["Pulmonary av malformation"],"keywords":[]}
{"name":"Limb-girdle muscular dystrophy, type 2S","alternate_symbols":["LGMD2S"],"id":"18193","type":"Disease","attribute_content":[],"symbol":"LGMDR18","medgen_id":"C4517996","xrefs":["{\"db\":\"OMIM\",\"id\":\"615356\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"369840\"}","{\"db\":\"OMIM\",\"id\":\"614138.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 18\"}","{\"db\":\"OMIM\",\"id\":\"614138.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 18\"}","{\"db\":\"OMIM\",\"id\":\"614138.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 18\"}","{\"db\":\"OMIM\",\"id\":\"614138.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 18\"}","{\"db\":\"OMIM\",\"id\":\"615356\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 18\"}","{\"db\":\"OMIM\",\"id\":\"615356\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"LGMD2S\"}","{\"db\":\"OMIM\",\"id\":\"615356\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["Autosomal recessive limb girdle muscular dystrophy type 2S","MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 18"],"keywords":[]}
{"name":"Interstitial lung and liver disease","alternate_symbols":[],"id":"18331","type":"Disease","attribute_content":[],"symbol":"ILLD","medgen_id":"C4225400","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014206\"}","{\"db\":\"OMIM\",\"id\":\"615486\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"440427\"}","{\"db\":\"OMIM\",\"id\":\"615486\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PULMONARY ALVEOLAR PROTEINOSIS, REUNION ISLAND\"}","{\"db\":\"OMIM\",\"id\":\"615486\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["PULMONARY ALVEOLAR PROTEINOSIS, REUNION ISLAND"],"keywords":[]}
{"name":"Cytosolic phospholipase-A2 alpha deficiency associated bleeding disorder","alternate_symbols":[],"id":"41562","type":"Disease","attribute_content":[],"symbol":"GURDP","medgen_id":"C5193061","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0018794\"}","{\"db\":\"OMIM\",\"id\":\"618372\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"477787\"}","{\"db\":\"OMIM\",\"id\":\"600522.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GASTROINTESTINAL ULCERATION, RECURRENT, WITH DYSFUNCTIONAL PLATELETS\"}","{\"db\":\"OMIM\",\"id\":\"600522.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GASTROINTESTINAL ULCERATION, RECURRENT, WITH DYSFUNCTIONAL PLATELETS\"}","{\"db\":\"OMIM\",\"id\":\"600522.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GASTROINTESTINAL ULCERATION, RECURRENT, WITH DYSFUNCTIONAL PLATELETS\"}","{\"db\":\"OMIM\",\"id\":\"600522.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GASTROINTESTINAL ULCERATION, RECURRENT, WITH DYSFUNCTIONAL PLATELETS\"}","{\"db\":\"OMIM\",\"id\":\"618372\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GASTROINTESTINAL ULCERATION, RECURRENT, WITH DYSFUNCTIONAL PLATELETS\"}","{\"db\":\"OMIM\",\"id\":\"618372\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PHOSPHOLIPASE A2, GROUP IVA, DEFICIENCY OF\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0018794\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618372\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["GASTROINTESTINAL ULCERATION, RECURRENT, WITH DYSFUNCTIONAL PLATELETS","PHOSPHOLIPASE A2, GROUP IVA, DEFICIENCY OF"],"keywords":[]}
{"name":"Elsahy-Waters syndrome","alternate_symbols":[],"id":"628","type":"Disease","attribute_content":[],"symbol":"ESWS","medgen_id":"C0809936","xrefs":["{\"db\":\"OMIM\",\"id\":\"211380\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1299\"}","{\"db\":\"Orphanet\",\"id\":\"157788\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Brachioskeletogenital+Syndrome/914\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Brachioskeletogenital syndrome\"}","{\"db\":\"OMIM\",\"id\":\"211380\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["BSG syndrome","Brachioskeletogenital syndrome","Hypospadias, hypertelorism, upper lid coloboma, and mixed-type hearing loss"],"keywords":[]}
{"name":"Nasopharyngeal Neoplasms","alternate_symbols":[],"id":"36990","type":"Disease","attribute_content":[],"medgen_id":"C0027439","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100630\",\"type\":\"primary\"}","{\"db\":\"MeSH\",\"id\":\"D009303\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100630\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Nasopharyngeal neoplasm\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100630\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Neoplasia of the nasopharynx\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100630\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Neoplasm of the nasopharynx\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100630\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Tumor of the nasopharynx\"}"],"alternate_names":["Nasopharyngeal neoplasm","Neoplasia of the nasopharynx","Neoplasm of the nasopharynx","Tumor of the nasopharynx"],"keywords":[]}
{"name":"Chromosome 2q37 deletion syndrome","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301337\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1158\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":[],"id":"1058","type":"Disease","attribute_content":[],"symbol":"BDMR","medgen_id":"C2931817","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010886\"}","{\"db\":\"OMIM\",\"id\":\"600430\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1001\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10202\",\"ref_field\":\"gard_id\"}","{\"db\":\"SNOMED CT\",\"id\":\"702357000\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"600430\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"gard_id":"10202","alternate_names":["Albright hereditary osteodystrophy-like syndrome","Brachydactyly-Mental Retardation syndrome","Chromosome 2, monosomy 2q37","Deletion 2q37","Monosomy 2q37"],"keywords":[]}
{"name":"Infantile liver failure syndrome 2","alternate_symbols":[],"id":"33970","type":"Disease","attribute_content":[],"symbol":"ILFS2","medgen_id":"C3809651","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014659\"}","{\"db\":\"OMIM\",\"id\":\"616483\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"464724\"}"],"alternate_names":[],"keywords":[]}
{"name":"Hodgkin lymphoma","alternate_symbols":[],"id":"5259","type":"Disease","attribute_content":[],"symbol":"CHL","medgen_id":"C0019829","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0012189\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"236000\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"391\"}","{\"db\":\"Orphanet\",\"id\":\"98293\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0012189\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hodgkin disease\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0012189\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hodgkin's lymphoma\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hodgkin+lymphoma/3444\",\"ref_field\":\"name\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0012189\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"2714\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"236000\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["Hodgkin disease","Hodgkin's lymphoma"],"keywords":[]}
{"name":"Combined immunodeficiency, X-linked","alternate_symbols":["IMD6","XCID"],"id":"1537","type":"Disease","attribute_content":[],"symbol":"CIDX","medgen_id":"CN030319","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010730\"}","{\"db\":\"OMIM\",\"id\":\"312863\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"312863\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 6\"}","{\"db\":\"OMIM\",\"id\":\"312863\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"IMD6\"}","{\"db\":\"OMIM\",\"id\":\"312863\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"XCID\"}","{\"db\":\"Genetic Alliance\",\"id\":\"COMBINED+IMMUNODEFICIENCY%2C+X-LINKED/8010\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"312863\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["IMMUNODEFICIENCY 6"],"keywords":[]}
{"name":"Brachydactyly type E1","alternate_symbols":["BDE"],"id":"525","type":"Disease","attribute_content":[],"symbol":"BDE1","medgen_id":"C1862102","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005863\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006115\",\"type\":\"secondary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0007223\"}","{\"db\":\"OMIM\",\"id\":\"113300\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"93387\"}","{\"db\":\"OMIM\",\"id\":\"113300\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"BRACHYDACTYLY, TYPE E\"}","{\"db\":\"OMIM\",\"id\":\"142989.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"BRACHYDACTYLY, TYPE E\"}","{\"db\":\"OMIM\",\"id\":\"142989.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"BRACHYDACTYLY, TYPE E\"}","{\"db\":\"OMIM\",\"id\":\"113300\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"BDE\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Brachydactyly+type+E1/7860\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"113300\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["BRACHYDACTYLY, TYPE E"],"keywords":[]}
{"name":"Namaqualand hip dysplasia","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"31021589\",\"@Source\":\"PubMed\"},{\"$\":\"NBK540447\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":["NHD"],"id":"3131","type":"Disease","attribute_content":[],"symbol":"OSCDP","medgen_id":"C0432214","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011496\"}","{\"db\":\"OMIM\",\"id\":\"604864\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"93279\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Osteoarthritis+with+mild+chondrodysplasia/9052\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Osteoarthritis with mild chondrodysplasia\"}","{\"db\":\"OMIM\",\"id\":\"604864\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"NHD\"}","{\"db\":\"SNOMED CT\",\"id\":\"254064009\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"604864\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["Osteoarthritis with mild chondrodysplasia"],"keywords":[]}
{"name":"Preaxial hand polydactyly","alternate_symbols":[],"id":"22226","type":"Finding","attribute_content":[],"symbol":"PPD1","medgen_id":"C1395852","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001177\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005629\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005634\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006182\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0009604\",\"type\":\"secondary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0008269\"}","{\"db\":\"OMIM\",\"id\":\"174400\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"93339\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001177\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Extra thumb\"}","{\"db\":\"OMIM\",\"id\":\"174400\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FROMONT ANOMALY\"}","{\"db\":\"OMIM\",\"id\":\"174400\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"POLYDACTYLY, PREAXIAL\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001177\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Polydactyly affecting the thumb\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001177\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Preaxial polydactyly of hands\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001177\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Supernumerary thumb\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4417\",\"ref_field\":\"gard_id\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001177\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"174400\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"gard_id":"4417","alternate_names":["Extra thumb","FROMONT ANOMALY","POLYDACTYLY, PREAXIAL","Polydactyly affecting the thumb","Polydactyly, preaxial I","Preaxial polydactyly of hands","Supernumerary thumb","Thumb polydactyly"],"keywords":[]}
{"name":"Lethal Kniest-like syndrome","alternate_symbols":[],"id":"1129","type":"Disease","attribute_content":[],"symbol":"DDSH","medgen_id":"C1857100","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009140\"}","{\"db\":\"OMIM\",\"id\":\"224410\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1865\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"2026\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Kniest+like+dysplasia+lethal/4021\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"93132001\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"224410\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"gard_id":"2026","alternate_names":["Anisospondylic camptomicromelic dwarfism Silverman-Handmaker type","Dyssegmental Dysplasia","Dyssegmental dwarfism Silverman-Handmaker type"],"keywords":[]}
{"name":"Craniosynostosis syndrome","content":"{\"Citation\":{\"@Type\":\"review\",\"ID\":{\"$\":\"21082653\",\"@Source\":\"PubMed\"}}}","alternate_symbols":[],"id":"16781","type":"Disease","attribute_content":[],"medgen_id":"C0010278","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001363\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001365\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004494\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005448\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005457\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005467\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0008492\",\"type\":\"secondary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0015469\"}","{\"db\":\"MeSH\",\"id\":\"D003398\"}","{\"db\":\"OMIM\",\"id\":\"PS123100\",\"type\":\"Phenotypic series\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001363\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cranial suture synostosis\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001363\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Craniostenosis\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001363\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Craniosynostosis\"}","{\"db\":\"OMIM\",\"id\":\"PS123100\",\"type\":\"Phenotypic series\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Craniosynostosis\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001363\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Craniosyostosis\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001363\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Deformity of the skull\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001363\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Early fusion of cranial sutures\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001363\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Premature closure of cranial sutures\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001363\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Premature fontanel closure\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001363\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Premature suture closure\"}","{\"db\":\"SNOMED CT\",\"id\":\"57219006\",\"ref_field\":\"name\"}"],"alternate_names":["Cranial suture synostosis","Craniostenosis","Craniosynostosis","Craniosyostosis","Deformity of the skull","Early fusion of cranial sutures","Premature closure of cranial sutures","Premature fontanel closure","Premature suture closure"],"keywords":[]}
{"name":"Congenital malrotation of intestine","alternate_symbols":[],"id":"17263","type":"Finding","attribute_content":[],"medgen_id":"C0221210","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002026\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002566\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0008666\"}","{\"db\":\"OMIM\",\"id\":\"193250\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2454\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002566\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Gut malrotation\"}","{\"db\":\"OMIM\",\"id\":\"193250\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"INTESTINAL MALROTATION, FAMILIAL\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002566\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Intestinal malrotation\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002566\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Malrotation\"}","{\"db\":\"SNOMED CT\",\"id\":\"29980002\",\"ref_field\":\"name\"}"],"alternate_names":["Gut malrotation","INTESTINAL MALROTATION, FAMILIAL","Intestinal malrotation","Malrotation","Volvulus of midgut"],"keywords":[]}
{"name":"Vertical talus, congenital","alternate_symbols":[],"id":"4490","type":"Disease","attribute_content":[],"symbol":"CVT","medgen_id":"C0240912","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001835\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001838\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004693\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0010218\",\"type\":\"secondary\"}","{\"db\":\"OMIM\",\"id\":\"192950\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"178382\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001838\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Rocker-bottom feet\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001838\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Rockerbottom feet\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Vertical+talus%2C+congenital/7388\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"192950\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["Pes valgus, congenital convex","Rocker-bottom feet","Rocker-bottom foot deformity","Rockerbottom feet"],"keywords":[]}
{"name":"Holoprosencephaly 1","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301702\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1530\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":[],"id":"8942","type":"Disease","attribute_content":[],"symbol":"HPE1","medgen_id":"C0266667","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0009914\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0009349\"}","{\"db\":\"OMIM\",\"id\":\"236100\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2162\"}","{\"db\":\"Orphanet\",\"id\":\"268936\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0009914\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cyclopia\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0009914\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cyclops eye\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0009914\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Single central eye\"}","{\"db\":\"OMIM\",\"id\":\"236100\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["Cyclopia","Cyclops eye","Single central eye"],"keywords":[]}
{"name":"Increased IgE level","alternate_symbols":[],"id":"23624","type":"Finding","attribute_content":[],"medgen_id":"C0236175","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0003212\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005382\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005418\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005433\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0003212\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Elevated immunoglobulin E\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0003212\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Elevated serum IgE\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0003212\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"High immunoglobulin E\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0003212\",\"ref_field\":\"name\"}"],"alternate_names":["Elevated immunoglobulin E","Elevated serum IgE","High immunoglobulin E","Ige, elevated level of"],"keywords":[]}
{"name":"Abducens nerve disorder","alternate_symbols":[],"id":"29250","type":"Finding","attribute_content":[],"medgen_id":"C0271355","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011349\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0020594\"}","{\"db\":\"SNOMED CT\",\"id\":\" 398963001\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Abducens nerve weakness\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011349\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Abducens palsy\"}","{\"db\":\"SNOMED CT\",\"id\":\" 398925009\",\"ref_field\":\"name\"}"],"alternate_names":["Abducens nerve weakness","Abducens palsy"],"keywords":[]}
{"name":"C4a deficiency","alternate_symbols":[],"id":"12744","type":"Disease","attribute_content":[],"symbol":"C4AD","medgen_id":"C3280642","xrefs":["{\"db\":\"OMIM\",\"id\":\"614380\",\"type\":\"MIM\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Complement+component+4a+deficiency/8026\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Complement component 4a deficiency\"}","{\"db\":\"OMIM\",\"id\":\"614380\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["Complement component 4a deficiency"],"keywords":[]}
{"name":"Deafness, autosomal dominant 22","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301607\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1434\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":[],"id":"935","type":"Disease","attribute_content":[],"symbol":"DFNA22","medgen_id":"C2931767","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011660\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0016424\"}","{\"db\":\"OMIM\",\"id\":\"606346\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"228012\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Deafness%2C+Autosomal+Dominant+Nonsyndromic+Sensorineural+22/2150\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Deafness, autosomal dominant nonsyndromic sensorineural 22\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0016424\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Progressive sensorineural hearing loss-hypertrophic cardiomyopathy syndrome\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9167\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Deafness%2C+autosomal+dominant+22/8137\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"606346\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"gard_id":"9167","alternate_names":["DFNA 22","Deafness, autosomal dominant nonsyndromic sensorineural 22","Progressive sensorineural hearing loss-hypertrophic cardiomyopathy syndrome"],"keywords":[]}
{"name":"Retinitis pigmentosa 50","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301590\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1417\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGentest, 2012\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"22234150\",\"@Source\":\"PubMed\"}}]}","alternate_symbols":[],"id":"6862","type":"Disease","attribute_content":[],"symbol":"RP50","medgen_id":"C2750789","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013175\"}","{\"db\":\"OMIM\",\"id\":\"613194\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"791\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Retinitis+pigmentosa+50/9237\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"613194\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["Retinitis pigmentosa, concentric"],"keywords":[]}
{"name":"Chilblain lupus 1","alternate_symbols":[],"id":"1425","type":"Disease","attribute_content":[],"symbol":"CHBL1","medgen_id":"C0024145","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012500\"}","{\"db\":\"OMIM\",\"id\":\"610448\",\"type\":\"MIM\"}","{\"db\":\"SNOMED CT\",\"id\":\"72470008\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Sarcoidosis, lupus pernio type\"}","{\"db\":\"OMIM\",\"id\":\"610448\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["Chilblain Lupus","Sarcoidosis, lupus pernio type"],"keywords":[]}
{"name":"Non-immune hydrops fetalis","content":"{\"Citation\":{\"@Abbrev\":\"EMQN, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25052315\",\"@Source\":\"PubMed\"}}}","alternate_symbols":[],"id":"14401","type":"Disease","attribute_content":[],"symbol":"NIHF","medgen_id":"C0455988","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001790\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0009369\"}","{\"db\":\"OMIM\",\"id\":\"236750\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"363999\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001790\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Non-immune fetal hydrops\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001790\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Nonimmune hydrops\"}","{\"db\":\"SNOMED CT\",\"id\":\"276509008\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"236750\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["Familial non-immune hydrops fetalis","Fetal edema","Idiopathic hydrops fetalis","Non-immune fetal hydrops","Nonimmune hydrops"],"keywords":[]}
{"name":"Trichothiodystrophy, nonphotosensitive 1","alternate_symbols":["ABHS","TTDN1"],"id":"3915","type":"Disease","attribute_content":[],"symbol":"TTD4","public_definition":"Trichothiodystrophy, which is commonly called TTD, is a rare inherited condition that affects many parts of the body. The hallmark of this condition is brittle hair that is sparse and easily broken. Tests show that the hair is lacking sulfur, an element that normally gives hair its strength.The signs and symptoms of trichothiodystrophy vary widely. Mild cases may involve only the hair. More severe cases also cause delayed development, significant intellectual disability, and recurrent infections; severely affected individuals may survive only into infancy or early childhood.Mothers of children with trichothiodystrophy may experience problems during pregnancy including pregnancy-induced high blood pressure (preeclampsia) and a related condition called HELLP syndrome that can damage the liver. Babies with trichothiodystrophy are at increased risk of premature birth, low birth weight, and slow growth.Most affected children have short stature compared to others their age. Intellectual disability and delayed development are common, although most affected individuals are highly social with an outgoing and engaging personality. Some have brain abnormalities that can be seen with imaging tests. Trichothiodystrophy is also associated with recurrent infections, particularly respiratory infections, which can be life-threatening. Other features of trichothiodystrophy can include dry, scaly skin (ichthyosis); abnormalities of the fingernails and toenails; clouding of the lens in both eyes from birth (congenital cataracts); poor coordination; and skeletal abnormalities.About half of all people with trichothiodystrophy have a photosensitive form of the disorder, which causes them to be extremely sensitive to ultraviolet (UV) rays from sunlight. They develop a severe sunburn after spending just a few minutes in the sun. However, for reasons that are unclear, they do not develop other sun-related problems such as excessive freckling of the skin or an increased risk of skin cancer. Many people with trichothiodystrophy report that they do not sweat.","medgen_id":"C1313961","xrefs":["{\"db\":\"OMIM\",\"id\":\"234050\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"33364\"}","{\"db\":\"OMIM\",\"id\":\"234050\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"AMISH BRITTLE HAIR BRAIN SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"234050\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"BIDS SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"234050\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HAIR-BRAIN SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"234050\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"TRICHOTHIODYSTROPHY 4, NONPHOTOSENSITIVE\"}","{\"db\":\"OMIM\",\"id\":\"609188.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"TRICHOTHIODYSTROPHY 4, NONPHOTOSENSITIVE\"}","{\"db\":\"OMIM\",\"id\":\"609188.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"TRICHOTHIODYSTROPHY 4, NONPHOTOSENSITIVE\"}","{\"db\":\"OMIM\",\"id\":\"609188.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"TRICHOTHIODYSTROPHY 4, NONPHOTOSENSITIVE\"}","{\"db\":\"OMIM\",\"id\":\"609188.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"TRICHOTHIODYSTROPHY 4, NONPHOTOSENSITIVE\"}","{\"db\":\"OMIM\",\"id\":\"609188.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"TRICHOTHIODYSTROPHY 4, NONPHOTOSENSITIVE\"}","{\"db\":\"OMIM\",\"id\":\"234050\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ABHS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Trichothiodystrophy+nonphotosensitive/7210\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"trichothiodystrophy\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"234050\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["AMISH BRITTLE HAIR BRAIN SYNDROME","BIDS SYNDROME","HAIR-BRAIN SYNDROME","TRICHOTHIODYSTROPHY 4, NONPHOTOSENSITIVE","Trichothiodystrophy nonphotosensitive"],"keywords":[]}
{"name":"Mitochondrial DNA depletion syndrome 13 (encephalomyopathic type)","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"28383868\",\"@Source\":\"PubMed\"},{\"$\":\"NBK425540\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"29517884\",\"@Source\":\"PubMed\"},{\"$\":\"NBK487393\",\"@Source\":\"BookShelf\"}]}]}","alternate_symbols":[],"id":"18313","type":"Disease","attribute_content":[],"symbol":"MTDPS13","public_definition":"FBXL4-related encephalomyopathic mitochondrial DNA (mtDNA) depletion syndrome is a multi-system disorder characterized primarily by congenital or early-onset lactic acidosis and growth failure, feeding difficulty, hypotonia, and developmental delay. Other neurologic manifestations can include seizures, movement disorders, ataxia, autonomic dysfunction, and stroke-like episodes. All affected individuals alive at the time they were reported (median age: 3.5 years) demonstrated significant developmental delay. Other findings can involve the heart (hypertrophic cardiomyopathy, congenital heart malformations, arrhythmias), liver (mildly elevated transaminases), eyes (cataract, strabismus, nystagmus, optic atrophy), hearing (sensorineural hearing loss), and bone marrow (neutropenia, lymphopenia). Survival varies; the median age of reported deaths was two years (range 2 days â€“ 75 months), although surviving individuals as old as 36 years have been reported. To date FBXL4-related mtDNA depletion syndrome has been reported in 50 individuals.","medgen_id":"C3809592","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014198\"}","{\"db\":\"OMIM\",\"id\":\"615471\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"369897\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"13298\",\"ref_field\":\"gard_id\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK425540\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"615471\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"gard_id":"13298","alternate_names":[],"keywords":[]}
{"name":"Autosomal dominant distal renal tubular acidosis","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"31600044\",\"@Source\":\"PubMed\"},{\"$\":\"NBK547595\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":[],"id":"5855","type":"Disease","attribute_content":[],"symbol":"DRTA1","public_definition":"Individuals with hereditary distal renal tubular acidosis (dRTA) typically present in infancy with failure to thrive, although later presentations can occur, especially in individuals with autosomal dominant SLC4A1-dRTA. Initial clinical manifestations can also include emesis, polyuria, polydipsia, constipation, diarrhea, decreased appetite, and episodes of dehydration. Electrolyte manifestations include hyperchloremic non-anion gap metabolic acidosis and hypokalemia. Renal complications of dRTA include nephrocalcinosis, nephrolithiasis, medullary cysts, and impaired renal function. Additional manifestations include bone demineralization (rickets, osteomalacia), growth deficiency, sensorineural hearing loss (in ATP6V0A4-, ATP6V1B1-, and FOXI1-dRTA), and hereditary hemolytic anemia (in some individuals with SLC4A1-dRTA).","medgen_id":"CN280572","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008368\"}","{\"db\":\"OMIM\",\"id\":\"179800\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"93608\"}","{\"db\":\"OMIM\",\"id\":\"109270.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RENAL TUBULAR ACIDOSIS, DISTAL, 1\"}","{\"db\":\"OMIM\",\"id\":\"109270.0014\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RENAL TUBULAR ACIDOSIS, DISTAL, 1\"}","{\"db\":\"OMIM\",\"id\":\"109270.0020\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RENAL TUBULAR ACIDOSIS, DISTAL, 1\"}","{\"db\":\"OMIM\",\"id\":\"109270.0025\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RENAL TUBULAR ACIDOSIS, DISTAL, 1\"}","{\"db\":\"OMIM\",\"id\":\"179800\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RENAL TUBULAR ACIDOSIS, DISTAL, 1\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4668\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0008368\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK547595\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"179800\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"gard_id":"4668","alternate_names":["RENAL TUBULAR ACIDOSIS, DISTAL, 1","RTA, classic type","RTA, distal type, autosomal dominant","RTA, gradient type","Renal Tubular Acidosis, Type I","Renal tubular acidosis 1"],"keywords":[]}
{"name":"Epidermal nevus syndrome","alternate_symbols":["JNP"],"id":"4371","type":"Disease","attribute_content":[],"symbol":"SFM","public_definition":"Schimmelpenning-Feuerstein-Mims syndrome, also known as linear sebaceous nevus syndrome, is characterized by sebaceous nevi, often on the face, associated with variable ipsilateral abnormalities of the central nervous system, ocular anomalies, and skeletal defects (summary by Happle, 1991 and Ernst et al., 2007). The linear sebaceous nevi follow the lines of Blaschko (Hornstein and Knickenberg, 1974; Bouwes Bavinck and van de Kamp, 1985). All cases are sporadic. The syndrome is believed to be caused by an autosomal dominant lethal mutation that survives by somatic mosaicism (Gorlin et al., 2001).","medgen_id":"C4552097","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0010817\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"163200\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2612\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0010817\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Linear nevus sebaceous\"}","{\"db\":\"OMIM\",\"id\":\"164790.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC\"}","{\"db\":\"OMIM\",\"id\":\"190020.0017\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC\"}","{\"db\":\"OMIM\",\"id\":\"190020.0019\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC\"}","{\"db\":\"OMIM\",\"id\":\"190070.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC\"}","{\"db\":\"OMIM\",\"id\":\"163200\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"JNP\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Linear+nevus+sebaceous+syndrome/4248\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"239112008\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"163200\",\"type\":\"MIM\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"163200\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["Jadassohn nevus phakomatosis","Linear nevus sebaceous","Linear nevus sebaceous syndrome","Nevus sebaceus of Jadassohn","Nevus, Sebaceous of Jadassohn","Organoid nevus phakomatosis","SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC","SFM syndrome","Sebaceous nevus syndrome and hemimegalencephaly"],"keywords":[]}
{"name":"Dilated cardiomyopathy 1B","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301486\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1309\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"AHRQ, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"NBK248310\",\"@Source\":\"BookShelf\"}}]}","alternate_symbols":["CMPD1","FDC","FDCM"],"id":"32099","type":"Disease","attribute_content":[],"symbol":"CMD1B","public_definition":"Familial dilated cardiomyopathy is a genetic form of heart disease. It occurs when heart (cardiac) muscle becomes thin and weakened in at least one chamber of the heart, causing the open area of the chamber to become enlarged (dilated). As a result, the heart is unable to pump blood as efficiently as usual. To compensate, the heart attempts to increase the amount of blood being pumped through the heart, leading to further thinning and weakening of the cardiac muscle. Over time, this condition results in heart failure.It usually takes many years for symptoms of familial dilated cardiomyopathy to cause health problems. They typically begin in mid-adulthood, but can occur at any time from infancy to late adulthood. Signs and symptoms of familial dilated cardiomyopathy can include an irregular heartbeat (arrhythmia), shortness of breath (dyspnea), extreme tiredness (fatigue), fainting episodes (syncope), and swelling of the legs and feet. In some cases, the first sign of the disorder is sudden cardiac death. The severity of the condition varies among affected individuals, even in members of the same family.","medgen_id":"C0340427","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010951\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0016333\"}","{\"db\":\"OMIM\",\"id\":\"600884\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"PS115200\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"154\"}","{\"db\":\"Orphanet\",\"id\":\"217607\"}","{\"db\":\"OMIM\",\"id\":\"600884\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CARDIOMYOPATHY, FAMILIAL DILATED, 1\"}","{\"db\":\"Orphanet\",\"id\":\"217607\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Familial dilated cardiomyopathy\"}","{\"db\":\"OMIM\",\"id\":\"600884\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CMPD1\"}","{\"db\":\"OMIM\",\"id\":\"600884\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"FDC\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"familial-dilated-cardiomyopathy\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"600884\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["CARDIOMYOPATHY, FAMILIAL DILATED, 1","Familial dilated cardiomyopathy","Hypokinetic dilated cardiomyopathy, familial"],"keywords":[]}
{"name":"Charcot-Marie-Tooth disease, X-linked recessive, type 5","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301731\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1876\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301532\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1358\",\"@Source\":\"BookShelf\"}]}]}","alternate_symbols":[],"id":"1422","type":"Disease","attribute_content":[],"symbol":"CMTX5","public_definition":"X-linked Charcot-Marie-Tooth neuropathy type 5 (CMTX5), part of the spectrum of PRPS1-related disorders, is characterized by peripheral neuropathy, early-onset (prelingual) bilateral profound sensorineural hearing loss, and optic neuropathy. The onset of peripheral neuropathy is between ages five and 12 years. The lower extremities are affected earlier and more severely than upper extremities. Initial manifestations often include foot drop or gait disturbance. Onset of visual impairment is between ages seven and 20 years. Intellect and life span are normal. Carrier females do not have findings of CMTX5.","medgen_id":"C1839566","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009788\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010699\"}","{\"db\":\"OMIM\",\"id\":\"258650\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"311070\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"99014\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1876\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Charcot-Marie-Tooth Neuropathy X Type 5\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Rosenberg+Chutorian+syndrome/6361\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Optic atrophy polyneuropathy deafness\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0009788\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Optic atrophy, hearing loss, and peripheral neuropathy, autosomal recessive\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"114\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Charcot-Marie-Tooth+disease%2C+X-linked+recessive%2C+type+5/7964\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1876\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"311070\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"gard_id":"114","alternate_names":["Charcot-Marie-Tooth Neuropathy X Type 5","Familial opticoacoustic nerve degeneration and polyneuropathy","Optic atrophy polyneuropathy deafness","Optic atrophy, hearing loss, and peripheral neuropathy, autosomal recessive","Optic atrophy, neural deafness, and distal neurogenic amyotrophy","Optic atrophy, polyneuropathy, and deafness","Optic atrophy, sensorineural hearing loss and polyneuropathy","Rosenberg Chutorian syndrome"],"keywords":[]}
{"name":"Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 1","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301376\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1197\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":[],"id":"3988","type":"Disease","attribute_content":[],"symbol":"PLOSL1","public_definition":"Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL) is characterized by fractures (resulting from radiologically demonstrable polycystic osseous lesions), frontal lobe syndrome, and progressive presenile dementia beginning in the fourth decade. The clinical course of PLOSL can be divided into four stages: 1. The latent stage is characterized by normal early development. 2. The osseous stage (3rd decade of life) is characterized by pain and tenderness, mostly in ankles and feet, usually following strain or injury. Fractures are typically diagnosed several years later, most commonly in the bones of the extremities. 3. In the early neurologic stage (4th decade of life), a change of personality begins to develop insidiously. Affected individuals show a frontal lobe syndrome (loss of judgment, euphoria, loss of social inhibitions, disturbance of concentration, and lack of insight, libido, and motor persistence) leading to serious social problems. 4. The late neurologic stage is characterized by progressive dementia and loss of mobility. Death usually occurs before age 50 years.","medgen_id":"C4721893","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0020749\"}","{\"db\":\"OMIM\",\"id\":\"221770\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2770\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1197\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"221770\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"keywords":[]}
{"name":"Weill-Marchesani syndrome","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301293\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1114\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":["WMS"],"id":"9574","type":"Disease","attribute_content":[],"public_definition":"Weill-Marchesani syndrome (WMS) is a connective tissue disorder characterized by abnormalities of the lens of the eye, short stature, brachydactyly, joint stiffness, and cardiovascular defects. The ocular problems, typically recognized in childhood, include microspherophakia (small spherical lens), myopia secondary to the abnormal shape of the lens, ectopia lentis (abnormal position of the lens), and glaucoma, which can lead to blindness. Height of adult males is 142-169 cm; height of adult females is 130-157 cm. Autosomal recessive WMS cannot be distinguished from autosomal dominant WMS by clinical findings alone.","medgen_id":"C0265313","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0018096\"}","{\"db\":\"OMIM\",\"id\":\"PS277600\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"3449\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4936\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Weill-Marchesani+syndrome/7461\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"weill-marchesani-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"PS277600\",\"type\":\"Phenotypic series\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1114\",\"ref_field\":\"public_definition\"}"],"gard_id":"4936","alternate_names":["Mesodermal dysmorphodystrophy congenital","Spherophakia-brachymorphia syndrome","WM Syndrome"],"keywords":[]}
{"name":"Weill-Marchesani syndrome 2","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301293\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1114\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":["GEMSS"],"id":"5118","type":"Disease","attribute_content":[],"symbol":"WMS2","public_definition":"Weill-Marchesani syndrome (WMS) is a connective tissue disorder characterized by abnormalities of the lens of the eye, short stature, brachydactyly, joint stiffness, and cardiovascular defects. The ocular problems, typically recognized in childhood, include microspherophakia (small spherical lens), myopia secondary to the abnormal shape of the lens, ectopia lentis (abnormal position of the lens), and glaucoma, which can lead to blindness. Height of adult males is 142-169 cm; height of adult females is 130-157 cm. Autosomal recessive WMS cannot be distinguished from autosomal dominant WMS by clinical findings alone.","medgen_id":"C1869115","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012013\"}","{\"db\":\"OMIM\",\"id\":\"608328\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2084\"}","{\"db\":\"OMIM\",\"id\":\"608328\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MESODERMAL DYSMORPHODYSTROPHY, CONGENITAL\"}","{\"db\":\"OMIM\",\"id\":\"608328\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"GEMSS\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"2452\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Weill-Marchesani+syndrome+2/9473\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1114\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"608328\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"gard_id":"2452","alternate_names":["Glaucoma, Ectopia, Microspherophakia, Stiff joints and Short stature syndrome","MESODERMAL DYSMORPHODYSTROPHY, CONGENITAL","Weill-Marchesani Syndrome, Autosomal Dominant"],"keywords":[]}
{"name":"Disordered steroidogenesis due to cytochrome p450 oxidoreductase deficiency","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301592\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1419\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":[],"id":"12699","type":"Disease","attribute_content":[],"symbol":"ABS1","public_definition":"Cytochrome P450 oxidoreductase deficiency (PORD) is a disorder of steroidogenesis with a broad phenotypic spectrum including cortisol deficiency, altered sex steroid synthesis, disorders of sex development (DSD), and skeletal malformations of the Antley-Bixler syndrome (ABS) phenotype. Cortisol deficiency is usually partial, with some baseline cortisol production but failure to mount an adequate cortisol response in stress. Mild mineralocorticoid excess can be present and causes arterial hypertension, usually presenting in young adulthood. Manifestations of altered sex steroid synthesis include ambiguous genitalia/DSD in both males and females, large ovarian cysts in females, poor masculinization and delayed puberty in males, and maternal virilization during pregnancy with an affected fetus. Skeletal malformations can manifest as craniosynostosis, mid-face retrusion with proptosis and choanal stenosis or atresia, low-set dysplastic ears with stenotic external auditory canals, hydrocephalus, radiohumeral synostosis, neonatal fractures, congenital bowing of the long bones, joint contractures, arachnodactyly, and clubfeet; other anomalies observed include urinary tract anomalies (renal pelvic dilatation, vesicoureteral reflux). Cognitive impairment is of minor concern and likely associated with the severity of malformations; studies of developmental outcomes are lacking.","medgen_id":"C1860042","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013310\"}","{\"db\":\"OMIM\",\"id\":\"613571\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"95699\"}","{\"db\":\"OMIM\",\"id\":\"613571\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO CYTOCHROME P450 OXIDOREDUCTASE DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"613571\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DISORDERED STEROIDOGENESIS DUE TO POR DEFICIENCY\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"12664\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"cytochrome-p450-oxidoreductase-deficiency\",\"ref_field\":\"ghr_links\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Disordered+steroidogenesis+due+to+cytochrome+p450+oxidoreductase+deficiency/8271\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1419\",\"ref_field\":\"public_definition\"}"],"gard_id":"12664","ghr_links":"cytochrome P450 oxidoreductase deficiency","alternate_names":["ADRENAL HYPERPLASIA, CONGENITAL, DUE TO CYTOCHROME P450 OXIDOREDUCTASE DEFICIENCY","DISORDERED STEROIDOGENESIS DUE TO POR DEFICIENCY"],"keywords":[]}
{"name":"Spinocerebellar ataxia type 2","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301452\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1275\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301317\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1138\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EFNS, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20050888\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"EFNS/ENS, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24418350\",\"@Source\":\"PubMed\"}}]}","alternate_symbols":["OPCA2","SDSEM"],"id":"6240","type":"Disease","attribute_content":[],"symbol":"SCA2","public_definition":"Spinocerebellar ataxia type 2 (SCA2) is characterized by progressive cerebellar ataxia, including nystagmus, slow saccadic eye movements, and in some individuals, ophthalmoparesis or parkinsonism. Pyramidal findings are present; deep tendon reflexes are brisk early on and absent later in the course. Age of onset is typically in the fourth decade with a ten- to 15-year disease duration.","medgen_id":"C0752121","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008458\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010065\"}","{\"db\":\"OMIM\",\"id\":\"183090\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"271322\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"98756\"}","{\"db\":\"OMIM\",\"id\":\"183090\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CEREBELLAR DEGENERATION WITH SLOW EYE MOVEMENTS\"}","{\"db\":\"OMIM\",\"id\":\"183090\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OLIVOPONTOCEREBELLAR ATROPHY II\"}","{\"db\":\"OMIM\",\"id\":\"183090\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPINOCEREBELLAR ATROPHY II\"}","{\"db\":\"OMIM\",\"id\":\"183090\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"OPCA2\"}","{\"db\":\"OMIM\",\"id\":\"183090\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"SDSEM\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4072\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0008458\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1275\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"183090\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"gard_id":"4072","alternate_names":["CEREBELLAR DEGENERATION WITH SLOW EYE MOVEMENTS","OLIVOPONTOCEREBELLAR ATROPHY II","Olivopontocerebellar atrophy 2","Olivopontocerebellar atrophy Holguin type","SCA 2","SPINOCEREBELLAR ATROPHY II","Spinocerebellar ataxia Cuban type","Spinocerebellar ataxia with slow eye movements","Spinocerebellar atrophy 2","Wadia Swami syndrome"],"keywords":[]}
{"name":"RAHMAN SYNDROME","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"33270410\",\"@Source\":\"PubMed\"},{\"$\":\"NBK564966\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":[],"id":"37876","type":"Disease","attribute_content":[],"symbol":"RMNS","public_definition":"The name HIST1H1E syndrome has been proposed as a mnemonic for the characteristic features of this emerging, recognizable phenotype: hypotonia; intellectual disability with behavioral issues; skeletal; testes (undescended) and thyroid; heart anomalies (most commonly atrial septal defect); and ectodermal issues (including sparse hair, thin nails, and abnormal dentition). In the 47 affected individuals reported to date, predominant findings were intellectual disability (ranging from mild to profound) and behavioral problems (combinations of anxiety/phobias, obsessive behaviors, attention-deficit/hyperactivity disorder, and autistic spectrum disorder/traits among others). Skeletal involvement can include scoliosis and decreased bone mineral density. Other findings in some include seizures, craniosynostosis, and hearing loss. Life expectancy does not appear to be reduced in HIST1H1E syndrome.","medgen_id":"C4479637","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0044323\"}","{\"db\":\"OMIM\",\"id\":\"617537\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"142220.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"142220.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"142220.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617537\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK564966\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"617537\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"keywords":[]}
{"name":"Arterial tortuosity syndrome","content":"{\"Citation\":[{\"@Abbrev\":\"ACMG, 2012\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"22237449\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"25392904\",\"@Source\":\"PubMed\"},{\"$\":\"NBK253404\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ESC, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25173340\",\"@Source\":\"PubMed\"}}]}","alternate_symbols":["ATS"],"id":"437","type":"Disease","attribute_content":[],"symbol":"ATORS","public_definition":"Arterial tortuosity syndrome (ATS) is characterized by widespread elongation and tortuosity of the aorta and mid-sized arteries as well as focal stenosis of segments of the pulmonary arteries and/or aorta combined with findings of a generalized connective tissue disorder, which may include soft or doughy hyperextensible skin, joint hypermobility, inguinal hernia, and diaphragmatic hernia. Skeletal findings include pectus excavatum or carinatum, arachnodactyly, scoliosis, knee/elbow contractures, and camptodactyly. The cardiovascular system is the major source of morbidity and mortality with increased risk at any age for aneurysm formation and dissection both at the aortic root and throughout the arterial tree, and for ischemic vascular events involving cerebrovascular circulation (resulting in non-hemorrhagic stroke) and the abdominal arteries (resulting in infarctions of abdominal organs).","medgen_id":"C1859726","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008818\"}","{\"db\":\"OMIM\",\"id\":\"208050\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"3342\"}","{\"db\":\"OMIM\",\"id\":\"208050\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ATS\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"774\",\"ref_field\":\"gard_id\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK253404\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"208050\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"gard_id":"774","alternate_names":[],"keywords":[]}
{"name":"Glycogen storage disease XI","alternate_symbols":[],"id":"6906","type":"Disease","attribute_content":[],"symbol":"GSD11","public_definition":"Lactate dehydrogenase deficiency is a condition that affects how the body breaks down sugar to use as energy in cells, primarily muscle cells.There are two types of this condition: lactate dehydrogenase-A deficiency (sometimes called glycogen storage disease XI) and lactate dehydrogenase-B deficiency.People with lactate dehydrogenase-A deficiency experience fatigue, muscle pain, and cramps during exercise (exercise intolerance). In some people with lactate dehydrogenase-A deficiency, high-intensity exercise or other strenuous activity leads to the breakdown of muscle tissue (rhabdomyolysis). The destruction of muscle tissue releases a protein called myoglobin, which is processed by the kidneys and released in the urine (myoglobinuria). Myoglobin causes the urine to be red or brown. This protein can also damage the kidneys, in some cases leading to life-threatening kidney failure. Some people with lactate dehydrogenase-A deficiency develop skin rashes. The severity of the signs and symptoms among individuals with lactate dehydrogenase-A deficiency varies greatly.People with lactate dehydrogenase-B deficiency typically do not have any signs or symptoms of the condition. They do not have difficulty with physical activity or any specific physical features related to the condition. Affected individuals are usually discovered only when routine blood tests reveal reduced lactate dehydrogenase activity.","medgen_id":"C2931743","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013047\"}","{\"db\":\"OMIM\",\"id\":\"612933\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"284426\"}","{\"db\":\"OMIM\",\"id\":\"612933\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GSD XI\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Lactate+dehydrogenase+deficiency+type+A/4068\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Lactate dehydrogenase deficiency type A\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3160\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Fanconi+Bickel+Syndrome/2784\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"lactate-dehydrogenase-deficiency\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"612933\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"gard_id":"3160","alternate_names":["GSD XI","Lactate dehydrogenase deficiency type A"],"keywords":[]}
{"name":"McKusick-Kaufman syndrome","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301675\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1502\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":["HMCS"],"id":"2830","type":"Disease","attribute_content":[],"symbol":"MKKS","public_definition":"McKusick-Kaufman syndrome (MKS) is characterized by the combination of postaxial polydactyly (PAP), congenital heart disease (CHD), and hydrometrocolpos (HMC) in females and genital malformations in males (most commonly hypospadias, cryptorchidism, and chordee). HMC in infants usually presents as a large cystic abdominal mass arising out of the pelvis, caused by dilatation of the vagina and uterus as a result of the accumulation of cervical secretions from maternal estrogen stimulation. HMC can be caused by failure of the distal third of the vagina to develop (vaginal agenesis), a transverse vaginal membrane, or an imperforate hymen. PAP is the presence of additional digits on the ulnar side of the hand and the fibular side of the foot. A variety of congenital heart defects have been reported including atrioventricular canal, atrial septal defect, ventricular septal defect, or a complex congenital heart malformation.","medgen_id":"C0948368","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009367\"}","{\"db\":\"OMIM\",\"id\":\"236700\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2473\"}","{\"db\":\"OMIM\",\"id\":\"236700\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HMCS\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3427\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0009367\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1502\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"236700\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"gard_id":"3427","alternate_names":["Hydrometrocolpos syndrome","Hydrometrocolpos, postaxial polydactyly, and congenital heart malformation"],"keywords":[]}
{"name":"Colorectal cancer","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301390\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1211\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":[],"id":"32349","type":"Disease","attribute_content":[],"public_definition":"Lynch syndrome is characterized by an increased risk for colorectal cancer (CRC) and cancers of the endometrium, stomach, ovary, small bowel, hepatobiliary tract, urinary tract, brain, and skin. In individuals with Lynch syndrome the following lifetime risks for cancer are seen: CRC: 52%-82% (mean age at diagnosis 44-61 years). Endometrial cancer in females: 25%-60% (mean age at diagnosis 48-62 years). Gastric cancer: 6%-13% (mean age at diagnosis 56 years). Ovarian cancer: 4%-12% (mean age at diagnosis 42.5 years; ~30% are diagnosed \u003c age 40 years). The risk for other Lynch syndrome-related cancers is lower, though substantially increased over general population rates.","medgen_id":"C0009402","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0005575\"}","{\"db\":\"OMIM\",\"id\":\"114500\",\"type\":\"MIM\"}","{\"db\":\"CSER _CC_NCGL, University of Washington\",\"id\":\"UWMG_7884717\",\"ref_field\":\"name\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Colorectal+Cancer/1746\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1211\",\"ref_field\":\"public_definition\"}"],"alternate_names":[],"keywords":[]}
{"name":"Carcinoma of colon","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301390\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1211\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EGAPP, 2009\",\"@Type\":\"Position Statement\",\"ID\":{\"$\":\"2743612\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"EGAPP, 2009\",\"@Type\":\"Position Statement\",\"ID\":{\"$\":\"2743610\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"AMA/NCHPEG, 2012\",\"@Type\":\"Suggested Reading\",\"URL\":{\"$\":\"http://www.nchpeg.org/documents/crc/11-0456%20Fact%20sheets%20(MSI%20and%20IHC%20testing).pdf\"}},{\"@Abbrev\":\"NACB, 2008\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"19042984\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Imperiale et al., 2014\",\"@Type\":\"Suggested Reading\",\"ID\":{\"$\":\"25006736\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ASCO, 2006\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"17060676\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NCCN, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"22138009\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACP MPDG, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24996433\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"SEAP/SEOM, 2012\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"22855150\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ESMO, 2012\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23012255\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"SEAP/SEOM, 2015\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25373533\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"EGTM, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23852704\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"EGAPP, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23429431\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"AHRQ, 2013\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"Technology Assessment on Genetic Testing or Molecular Pathology Testing of Cancers with Unknown Primary Site to Determine Origin\"},\"URL\":{\"$\":\"https://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id90TA.pdf\"}}]}","alternate_symbols":[],"id":"10229","type":"Disease","attribute_content":[],"symbol":"CRC","public_definition":"Lynch syndrome is characterized by an increased risk for colorectal cancer (CRC) and cancers of the endometrium, stomach, ovary, small bowel, hepatobiliary tract, urinary tract, brain, and skin. In individuals with Lynch syndrome the following lifetime risks for cancer are seen: CRC: 52%-82% (mean age at diagnosis 44-61 years). Endometrial cancer in females: 25%-60% (mean age at diagnosis 48-62 years). Gastric cancer: 6%-13% (mean age at diagnosis 56 years). Ovarian cancer: 4%-12% (mean age at diagnosis 42.5 years; ~30% are diagnosed \u003c age 40 years). The risk for other Lynch syndrome-related cancers is lower, though substantially increased over general population rates.","medgen_id":"C0699790","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0002032\"}","{\"db\":\"SNOMED CT\",\"id\":\"269533000\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1211\",\"ref_field\":\"public_definition\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500646\",\"ref_field\":\"symbol\"}"],"alternate_names":["Colon cancer","Colon cancer, somatic","Colonic carcinoma","Colorectal cancer, somatic","Rectal cancer, somatic"],"keywords":["Hereditary cancer syndrome"]}
{"name":"Niemann-Pick disease, type C2","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301473\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1296\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":["AD-HIES"],"id":"3182","type":"Disease","attribute_content":[],"symbol":"NPC2","public_definition":"Niemann-Pick disease type C (NPC) is a slowly progressive lysosomal disorder whose principal manifestations are age dependent. The manifestations in the perinatal period and infancy are predominantly visceral, with hepatosplenomegaly, jaundice, and (in some instances) pulmonary infiltrates. From late infancy onward, the presentation is dominated by neurologic manifestations. The youngest children may present with hypotonia and developmental delay, with the subsequent emergence of ataxia, dysarthria, dysphagia, and, in some individuals, epileptic seizures, dystonia, and gelastic cataplexy. Although cognitive impairment may be subtle at first, it eventually becomes apparent that affected individuals have a progressive dementia. Older teenagers and young adults may present predominantly with apparent early-onset dementia or psychiatric manifestations; however, careful examination usually identifies typical neurologic signs.","medgen_id":"C1843366","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011873\"}","{\"db\":\"OMIM\",\"id\":\"607625\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"646\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3992\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011873\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1296\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"607625\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"gard_id":"3992","alternate_names":[],"keywords":[]}
{"name":"Niemann-Pick disease, type C","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301473\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1296\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":[],"id":"14995","type":"Disease","attribute_content":[],"symbol":"NPC","public_definition":"Niemann-Pick disease type C (NPC) is a slowly progressive lysosomal disorder whose principal manifestations are age dependent. The manifestations in the perinatal period and infancy are predominantly visceral, with hepatosplenomegaly, jaundice, and (in some instances) pulmonary infiltrates. From late infancy onward, the presentation is dominated by neurologic manifestations. The youngest children may present with hypotonia and developmental delay, with the subsequent emergence of ataxia, dysarthria, dysphagia, and, in some individuals, epileptic seizures, dystonia, and gelastic cataplexy. Although cognitive impairment may be subtle at first, it eventually becomes apparent that affected individuals have a progressive dementia. Older teenagers and young adults may present predominantly with apparent early-onset dementia or psychiatric manifestations; however, careful examination usually identifies typical neurologic signs.","medgen_id":"C0220756","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0018982\"}","{\"db\":\"Orphanet\",\"id\":\"646\"}","{\"db\":\"SNOMED CT\",\"id\":\"66751000\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1296\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"257220\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"keywords":[]}
{"name":"Niemann-Pick disease type C1","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301473\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1296\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":[],"id":"3637","type":"Disease","attribute_content":[],"symbol":"NPC1","public_definition":"Niemann-Pick disease type C (NPC) is a slowly progressive lysosomal disorder whose principal manifestations are age dependent. The manifestations in the perinatal period and infancy are predominantly visceral, with hepatosplenomegaly, jaundice, and (in some instances) pulmonary infiltrates. From late infancy onward, the presentation is dominated by neurologic manifestations. The youngest children may present with hypotonia and developmental delay, with the subsequent emergence of ataxia, dysarthria, dysphagia, and, in some individuals, epileptic seizures, dystonia, and gelastic cataplexy. Although cognitive impairment may be subtle at first, it eventually becomes apparent that affected individuals have a progressive dementia. Older teenagers and young adults may present predominantly with apparent early-onset dementia or psychiatric manifestations; however, careful examination usually identifies typical neurologic signs.","medgen_id":"C3179455","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009757\"}","{\"db\":\"OMIM\",\"id\":\"257220\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"646\"}","{\"db\":\"OMIM\",\"id\":\"257220\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"607623.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NIEMANN-PICK DISEASE, VARIANT TYPE C1\"}","{\"db\":\"OMIM\",\"id\":\"607623.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NIEMANN-PICK DISEASE, VARIANT TYPE C1\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7207\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Niemann-Pick+disease+type+C1/5223\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1296\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"257220\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"gard_id":"7207","alternate_names":["NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY","NIEMANN-PICK DISEASE, VARIANT TYPE C1","Neurovisceral storage disease with vertical supranuclear ophthalmoplegia","Niemann-Pick disease with cholesterol esterification block","Niemann-Pick disease, chronic neuronopathic form"],"keywords":[]}
{"name":"Lymphoproliferative syndrome 1, X-linked","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301580\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1406\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":["EBVS","IMD5","LYP","XLP","XLPD"],"id":"5424","type":"Disease","attribute_content":[],"symbol":"XLP1","public_definition":"X-linked lymphoproliferative disease (XLP) has two recognizable subtypes, XLP1 and XLP2. XLP1 is characterized predominantly by one of three commonly recognized phenotypes: Inappropriate immune response to Epstein-Barr virus (EBV) infection leading to hemophagocytic lymphohistiocytosis (HLH) or severe mononucleosis. Dysgammaglobulinemia. Lymphoproliferative disease (malignant lymphoma). XLP2 is most often characterized by HLH (often associated with EBV), dysgammaglobulinemia, and inflammatory bowel disease. HLH resulting from EBV infection is associated with an unregulated and exaggerated immune response with widespread proliferation of cytotoxic T cells, EBV-infected B cells, and macrophages. Dysgammaglobulinemia is typically hypogammaglobulinemia of one or more immunoglobulin subclasses. The malignant lymphomas are typically B-cell lymphomas, non-Hodgkin type, often extranodal, and in particular involving the intestine.","medgen_id":"CN034206","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0024551\"}","{\"db\":\"OMIM\",\"id\":\"308240\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2442\"}","{\"db\":\"Orphanet\",\"id\":\"538931\"}","{\"db\":\"OMIM\",\"id\":\"308240\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 5\"}","{\"db\":\"OMIM\",\"id\":\"308240\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY, X-LINKED PROGRESSIVE COMBINED VARIABLE\"}","{\"db\":\"OMIM\",\"id\":\"308240\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"INFECTIOUS MONONUCLEOSIS, SEVERE, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"308240\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EBVS\"}","{\"db\":\"OMIM\",\"id\":\"308240\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"IMD5\"}","{\"db\":\"OMIM\",\"id\":\"308240\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"LYP\"}","{\"db\":\"OMIM\",\"id\":\"308240\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"XLP\"}","{\"db\":\"OMIM\",\"id\":\"308240\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"XLPD\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7906\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Lymphoproliferative+syndrome+X-linked+1/4379\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1406\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"308240\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"gard_id":"7906","alternate_names":["Duncan disease","Duncan's syndrome","EBV infection severe susceptibility to","Epstein Barr virus infection familial fatal","IMMUNODEFICIENCY 5","IMMUNODEFICIENCY, X-LINKED PROGRESSIVE COMBINED VARIABLE","INFECTIOUS MONONUCLEOSIS, SEVERE, SUSCEPTIBILITY TO","Purtilo syndrome"],"keywords":[]}
{"name":"Miyoshi muscular dystrophy 1","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301480\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1303\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"AAN, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25313375\",\"@Source\":\"PubMed\"}}]}","alternate_symbols":[],"id":"2959","type":"Disease","attribute_content":[],"symbol":"MMD1","public_definition":"Dysferlinopathy includes a spectrum of muscle disease characterized by two main phenotypes: Miyoshi myopathy with primarily distal weakness and limb-girdle muscular dystrophy type 2B (LGMD2B) with primarily proximal weakness. Miyoshi myopathy (median age of onset 19 years) is characterized by muscle weakness and atrophy, most marked in the distal parts of the legs, especially the gastrocnemius and soleus muscles. Over a period of years, the weakness and atrophy spread to the thighs and gluteal muscles. The forearms may become mildly atrophic with decrease in grip strength; the small muscles of the hands are spared. LGMD2B is characterized by early weakness and atrophy of the pelvic and shoulder girdle muscles in adolescence or young adulthood, with slow progression. Other phenotypes are scapuloperoneal syndrome, distal myopathy with anterior tibial onset, elevated serum CK concentration only, and congenital muscular dystrophy.","medgen_id":"C4551973","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0024545\"}","{\"db\":\"OMIM\",\"id\":\"254130\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"45448\"}","{\"db\":\"NCI\",\"id\":\"C118846\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1303\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"254130\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"keywords":[]}
{"name":"Congenital plasminogen activator inhibitor type 1 deficiency","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"28771291\",\"@Source\":\"PubMed\"},{\"$\":\"NBK447152\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":[],"id":"6848","type":"Disease","attribute_content":[],"public_definition":"Untreated complete plasminogen activator inhibitor 1 (PAI-1) deficiency is characterized by mild-to-moderate bleeding, although in some instances bleeding can be life threatening. Most commonly, delayed bleeding is associated with injury, trauma, or surgery; spontaneous bleeding does not occur. While males and females with complete PAI-1 deficiency are affected equally, females may present more frequently with clinical manifestations or earlier in life than males due to menorrhagia and postpartum hemorrhage. Fewer than ten families with complete PAI-1 deficiency have been reported to date. The incidence of complete PAI-1 deficiency is higher than expected in the genetic isolate of the Old Order Amish population of eastern and southern Indiana due to a pathogenic founder variant. In one family from this Old Order Amish population, seven individuals had cardiac fibrosis ranging from minimal-to-moderate (6 individuals) to severe (1).","medgen_id":"C2750067","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013227\"}","{\"db\":\"OMIM\",\"id\":\"613329\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"465\"}","{\"db\":\"OMIM\",\"id\":\"613329\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERFIBRINOLYSIS DUE TO PAI1 DEFICIENCY\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Plasminogen+activator+inhibitor+type+1+deficiency/5796\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Plasminogen activator inhibitor type 1 deficiency\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4381\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0013227\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK447152\",\"ref_field\":\"public_definition\"}"],"gard_id":"4381","alternate_names":["HYPERFIBRINOLYSIS DUE TO PAI1 DEFICIENCY","Plasminogen activator inhibitor type 1 deficiency"],"keywords":[]}
{"name":"Deficiency of butyrylcholine esterase","alternate_symbols":["BCHE Ann Arbor"],"id":"6333","type":"Disease","attribute_content":[],"symbol":"BCHED","public_definition":"Pseudocholinesterase deficiency is a condition that results in increased sensitivity to certain muscle relaxant drugs used during general anesthesia, called choline esters. These fast-acting drugs, such as succinylcholine and mivacurium, are given to relax the muscles used for movement (skeletal muscles), including the muscles involved in breathing. The drugs are often employed for brief surgical procedures or in emergencies when a breathing tube must be inserted quickly. Normally, these drugs are broken down (metabolized) by the body within a few minutes of being administered, at which time the muscles can move again. However, people with pseudocholinesterase deficiency may not be able to move or breathe on their own for a few hours after the drugs are administered. Affected individuals must be supported with a machine to help them breathe (mechanical ventilation) until the drugs are cleared from the body.People with pseudocholinesterase deficiency may also have increased sensitivity to certain other drugs, including the local anesthetic procaine, and to specific agricultural pesticides. The condition causes no other signs or symptoms and is usually not discovered until an abnormal drug reaction occurs.","medgen_id":"C1283400","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0015270\"}","{\"db\":\"OMIM\",\"id\":\"617936\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"132\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0015270\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Butyrylcholinesterase deficiency\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7482\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Pseudocholinesterase+deficiency/6025\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"360589003\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"pseudocholinesterase-deficiency\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"617936\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"gard_id":"7482","alternate_names":["Acylcholine acylhydrolase deficiency","BCHE deficiency","BCHE, silent 1","Butyrylcholinesterase deficiency","CHE1 deficiency","Mivacurium response","Pseudocholinesterase E1 deficiency","Succinylcholine response"],"keywords":["Pharmacogenetic"]}
{"name":"Intellectual disability, X-linked 21","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301604\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1431\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":["MRX34"],"id":"5490","type":"Disease","attribute_content":[],"symbol":"MRX21","public_definition":"NR0B1-related adrenal hypoplasia congenita includes both X-linked adrenal hypoplasia congenita (X-linked AHC) and Xp21 deletion (previously called complex glycerol kinase deficiency). X-linked AHC is characterized by primary adrenal insufficiency and/or hypogonadotropic hypogonadism (HH). Adrenal insufficiency is acute infantile onset (average age 3 weeks) in approximately 60% of affected males and childhood onset (ages 1-9 years) in approximately 40%. HH typically manifests in a male with adrenal insufficiency as delayed puberty (i.e., onset age \u003e14 years) and less commonly as arrested puberty at about Tanner Stage 3. Rarely, X-linked AHC manifests initially in early adulthood as delayed-onset adrenal insufficiency, partial HH, and/or infertility. Heterozygous females very occasionally have manifestations of adrenal insufficiency or hypogonadotropic hypogonadism. Xp21 deletion includes deletion of NR0B1 (causing X-linked AHC) and GK (causing glycerol kinase deficiency), and in some cases deletion of DMD (causing Duchenne muscular dystrophy). Developmental delay has been reported in males with Xp21 deletion when the deletion extends proximally to include DMD or when larger deletions extend distally to include IL1RAPL1 and DMD.","medgen_id":"C0796241","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010256\"}","{\"db\":\"OMIM\",\"id\":\"300143\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"777\"}","{\"db\":\"OMIM\",\"id\":\"300143\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MENTAL RETARDATION, X-LINKED 34\"}","{\"db\":\"Genetic Alliance\",\"id\":\"X-linked+mental+retardation+21/9497\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Mental retardation 21, X-linked\"}","{\"db\":\"OMIM\",\"id\":\"300143\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MRX34\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010256\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1431\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"300143\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["MENTAL RETARDATION, X-LINKED 34","Mental retardation 21, X-linked","Mental retardation, X-linked 21/34"],"keywords":[]}
{"name":"Thrombocytopenia 5","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"33226740\",\"@Source\":\"PubMed\"},{\"$\":\"NBK564234\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":[],"id":"32711","type":"Disease","attribute_content":[],"symbol":"THC5","public_definition":"Individuals with ETV6 thrombocytopenia and predisposition to leukemia most often present with a lifelong history of thrombocytopenia, which is usually in the mild to moderate range. No syndromic features or associations are consistently shared across pedigrees. Affected individuals also have a moderate risk of developing a hematologic malignancy (with B-cell acute lymphoblastic leukemia [B-ALL] being the most common) and possibly other malignant solid tumors, particularly colorectal cancer.","medgen_id":"C4015537","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014536\"}","{\"db\":\"OMIM\",\"id\":\"616216\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"616216\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"THROMBOCYTOPENIA 5 WITH INCREASED SUSCEPTIBILITY TO MALIGNANCY\"}","{\"db\":\"OMIM\",\"id\":\"616216\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"THROMBOCYTOPENIA, AUTOSOMAL DOMINANT, 5\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK564234\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"616216\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["THROMBOCYTOPENIA 5 WITH INCREASED SUSCEPTIBILITY TO MALIGNANCY","THROMBOCYTOPENIA, AUTOSOMAL DOMINANT, 5"],"keywords":[]}
{"name":"Maturity-onset diabetes of the young, type 2","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"29792621\",\"@Source\":\"PubMed\"},{\"$\":\"NBK500456\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":[],"id":"5458","type":"Disease","attribute_content":[],"symbol":"MODY2","medgen_id":"C0342277","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007453\"}","{\"db\":\"OMIM\",\"id\":\"125851\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"552\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512295\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512817\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552325\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552542\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552544\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556820\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556824\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000557910\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558434\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000559250\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568234\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000570044\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10657\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"maturity-onset-diabetes-of-the-young\",\"ref_field\":\"ghr_links\"}","{\"db\":\"OMIM\",\"id\":\"125851\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"disease_mechanism":"loss of function","gard_id":"10657","ghr_links":"maturity-onset diabetes of the young","alternate_names":["Diabetes mellitus MODY type 2","Diabetes mellitus, type II, autosomal dominant","MODY glucokinase-related","MODY type 2"],"disease_mechanism_id":"273","keywords":[]}
{"name":"Long QT syndrome","content":"{\"Citation\":[{\"@Abbrev\":\"AHRQ, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"NBK248310\",\"@Source\":\"BookShelf\"}},{\"@Abbrev\":\"HRS/EHRA/APHRS, 2013\",\"@Type\":\"Suggested Reading\",\"ID\":{\"$\":\"23994779\",\"@Source\":\"PubMed\"}}]}","mode_of_inheritance":"Various modes of inheritance","alternate_symbols":["LQT"],"id":"16506","type":"Disease","attribute_content":[],"symbol":"LQTS","medgen_id":"C0023976","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0002442\"}","{\"db\":\"MeSH\",\"id\":\"D008133\"}","{\"db\":\"OMIM\",\"id\":\"PS192500\",\"type\":\"Phenotypic series\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501111\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000511116\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515873\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519089\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520063\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520446\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520456\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520458\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520478\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522197\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522200\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000523361\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000525920\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528497\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528500\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528536\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552174\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552322\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000555634\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558315\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000559512\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000591169\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000592276\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Long+QT+Syndrome/4296\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"PS192500\",\"type\":\"Phenotypic series\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"9651007\",\"ref_field\":\"name\"}"],"disease_mechanism":"loss of function","alternate_names":[],"disease_mechanism_id":"273","keywords":[]}
{"name":"Familial hyperinsulinism","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301549\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1375\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":[],"id":"9496","type":"Disease","attribute_content":[],"public_definition":"Congenital hyperinsulinism is a condition that causes individuals to have abnormally high levels of insulin, which is a hormone that helps control blood sugar levels. People with this condition have frequent episodes of low blood sugar (hypoglycemia). In infants and young children, these episodes are characterized by a lack of energy (lethargy), irritability, or difficulty feeding. Repeated episodes of low blood sugar increase the risk for serious complications such as breathing difficulties, seizures, intellectual disability, vision loss, brain damage, and coma.The severity of congenital hyperinsulinism varies widely among affected individuals, even among members of the same family. About 60 percent of infants with this condition experience a hypoglycemic episode within the first month of life. Other affected children develop hypoglycemia by early childhood. Unlike typical episodes of hypoglycemia, which occur most often after periods without food (fasting) or after exercising, episodes of hypoglycemia in people with congenital hyperinsulinism can also occur after eating.","medgen_id":"C3888018","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0017182\"}","{\"db\":\"Orphanet\",\"id\":\"276525\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000320500\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000559250\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000561792\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569442\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000570010\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000570054\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000571198\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000591289\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"congenital-hyperinsulinism\",\"ref_field\":\"public_definition\"}"],"disease_mechanism":"loss of function","alternate_names":[],"disease_mechanism_id":"273","keywords":[]}
{"name":"Williams syndrome","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301427\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1249\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACC/AHA, 2008\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"19038677\",\"@Source\":\"PubMed\"}}]}","alternate_symbols":["WMS","WS"],"id":"5123","type":"Disease","attribute_content":[],"symbol":"WBS","public_definition":"Williams syndrome (WS) is characterized by cardiovascular disease (elastin arteriopathy, peripheral pulmonary stenosis, supravalvar aortic stenosis, hypertension), distinctive facies, connective tissue abnormalities, intellectual disability (usually mild), a specific cognitive profile, unique personality characteristics, growth abnormalities, and endocrine abnormalities (hypercalcemia, hypercalciuria, hypothyroidism, and early puberty). Feeding difficulties often lead to poor weight gain in infancy. Hypotonia and hyperextensible joints can result in delayed attainment of motor milestones.","medgen_id":"C0175702","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008678\"}","{\"db\":\"OMIM\",\"id\":\"194050\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"904\"}","{\"db\":\"OMIM\",\"id\":\"194050\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHROMOSOME 7q11.23 DELETION SYNDROME, 1.5- TO 1.8-MB\"}","{\"db\":\"OMIM\",\"id\":\"194050\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"WMS\"}","{\"db\":\"OMIM\",\"id\":\"194050\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"WS\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000314228\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508950\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519140\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520014\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521643\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000525881\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528542\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000529011\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000531722\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568029\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7891\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Williams+syndrome/7501\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"williams-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"63247009\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1249\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"194050\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"disease_mechanism":"loss of function","gard_id":"7891","alternate_names":["CHROMOSOME 7q11.23 DELETION SYNDROME, 1.5- TO 1.8-MB","Williams-Beuren syndrome"],"disease_mechanism_id":"273","keywords":[]}
{"name":"Larsen syndrome","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301736\",\"@Source\":\"PubMed\"},{\"$\":\"NBK2534\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":["LRS1"],"id":"14587","type":"Disease","attribute_content":["{\"Attribute\":{\"$\":\"The FLNB disorders include a spectrum of phenotypes ranging from mild to severe. At the mild end are spondylocarpotarsal synostosis (SCT) syndrome and Larsen syndrome; at the severe end are the phenotypic continuum of atelosteogenesis types I (AOI) and III (AOIII) and Piepkorn osteochondrodysplasia (POCD). SCT syndrome is characterized by postnatal disproportionate short stature, scoliosis and lordosis, clubfeet, hearing loss, dental enamel hypoplasia, carpal and tarsal synostosis, and vertebral fusions. Larsen syndrome is characterized by congenital dislocations of the hip, knee, and elbow; clubfeet (equinovarus or equinovalgus foot deformities); scoliosis and cervical kyphosis, which can be associated with a cervical myelopathy; short, broad, spatulate distal phalanges; distinctive craniofacies (prominent forehead, depressed nasal bridge, malar flattening, and widely spaced eyes); vertebral anomalies; and supernumerary carpal and tarsal bone ossification centers. Individuals with SCT syndrome and Larsen syndrome can have midline cleft palate and hearing loss. AOI and AOIII are characterized by severe short-limbed dwarfism; dislocated hips, knees, and elbows; and clubfeet. AOI is lethal in the perinatal period. In individuals with AOIII, survival beyond the neonatal period is possible with intensive and invasive respiratory support. Piepkorn osteochondrodysplasia (POCD) is a perinatal-lethal micromelic dwarfism characterized by flipper-like limbs (polysyndactyly with complete syndactyly of all fingers and toes, hypoplastic or absent first digits, and duplicated intermediate and distal phalanges), macrobrachycephaly, prominant forehead, hypertelorism, and exophthalmos. Occasional features include cleft palate, omphalocele, and cardiac and genitourinary anomalies. The radiographic features at mid-gestation are characteristic.\",\"@Type\":\"public definition\"},\"XRef\":{\"@DB\":\"GeneReviews\",\"@ID\":\"NBK2534\"}}"],"symbol":"LRS","public_definition":"Larsen syndrome is a disorder that affects the development of bones throughout the body. The signs and symptoms of Larsen syndrome vary widely even within the same family. Affected individuals are usually born with dislocations of the hips, knees, or elbows. Foot abnormalities, such as inward- and upward-turning feet (clubfeet), are also common. Affected individuals generally have small extra bones in their wrists and ankles that are visible on x-ray images. The tips of their fingers, especially the thumbs, are typically blunt and square-shaped (spatulate).Characteristic facial features in people with Larsen syndrome include a prominent forehead (frontal bossing), flattening of the bridge of the nose and middle of the face (midface hypoplasia), and wide-set eyes (ocular hypertelorism). Many people with Larsen syndrome have an opening in the roof of the mouth (a cleft palate). Affected individuals may also have hearing loss caused by malformations in tiny bones in the ears (ossicles).Short stature is a common feature of Larsen syndrome. In addition, people with the condition may have an unusually large range of joint movement (hypermobility) or joint deformities (contractures) that restrict movement. People with Larsen syndrome can also have abnormal curvature of the spine (kyphosis or scoliosis) that can impair breathing or compress the spinal cord and lead to weakness of the limbs. Some affected individuals experience respiratory problems, such as partial closing of the airways, short pauses in breathing (apnea), and frequent respiratory infections. Heart and kidney problems can also occur in people with Larsen syndrome. People with this condition can survive into adulthood. Their intellectual function is usually unaffected.","medgen_id":"C0175778","xrefs":["{\"db\":\"OMIM\",\"id\":\"150250\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"503\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Larsen+syndrome%2C+dominant+type/4094\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Larsen syndrome, dominant type\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508858\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522271\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522272\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Larsen+syndrome/4093\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"larsen-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"63387002\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"larsen-syndrome\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"150250\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"disease_mechanism":"loss of function","alternate_names":["Bilateral dislocation of the knees, pes cavus, cylindrically shaped fingers and characteristic facies","Larsen syndrome, dominant type"],"disease_mechanism_id":"273","keywords":[]}
{"name":"Fabry disease","content":"{\"Citation\":[{\"@Type\":\"general\",\"ID\":{\"$\":\"3009617\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301469\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1292\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"HFSA, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20610207\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2002\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"12735292\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Eng et al., 2006\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"16980809\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Salviati et al, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"2869001\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"EuroGentest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21934708\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"AHA/ASA, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25355838\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23860966\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ESC, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25173338\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]}]}","alternate_symbols":[],"id":"1790","type":"Disease","attribute_content":["{\"Attribute\":{\"$\":\"loss of function\",\"@Type\":\"disease mechanism\",\"@integerValue\":\"273\"},\"XRef\":[{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000246735\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000260631\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520063\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520447\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528528\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000552214\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556520\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000558532\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000325415\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000512526\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528276\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528500\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528536\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556501\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000505068\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507480\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507942\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000522527\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000568367\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000591289\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000514924\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520414\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528516\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000551442\"}]}"],"public_definition":"Fabry disease results from deficient activity of the enzyme alpha-galactosidase A (a-Gal A) and progressive lysosomal deposition of globotriaosylceramide (GL-3) in cells throughout the body. The classic form, occurring in males with less than 1% a-Gal A enzyme activity, usually has its onset in childhood or adolescence with periodic crises of severe pain in the extremities (acroparesthesia), the appearance of vascular cutaneous lesions (angiokeratomas), sweating abnormalities (anhidrosis, hypohidrosis, and rarely hyperhidrosis), characteristic corneal and lenticular opacities, and proteinuria. Gradual deterioration of renal function to end-stage renal disease (ESRD) usually occurs in men in the third to fifth decade. In middle age, most males successfully treated for ESRD develop cardiac and/or cerebrovascular disease, a major cause of morbidity and mortality. Heterozygous females typically have milder symptoms at a later age of onset than males. Rarely, they may be relatively asymptomatic throughout a normal life span or may have symptoms as severe as those observed in males with the classic phenotype. In contrast, males with greater than 1% a-Gal A activity may have: (1) a cardiac variant phenotype that usually presents in the sixth to eighth decade with left ventricular hypertrophy, cardiomyopathy and arrhythmia, and proteinuria, but without ESRD; or (2) a renal variant phenotype, associated with ESRD but without the skin lesions or pain; or (3) cerebrovascular disease presenting as stroke or transient ischemic attack.","medgen_id":"C0002986","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010526\"}","{\"db\":\"OMIM\",\"id\":\"301500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"324\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Angiokeratoma corporis diffusum\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry syndrome\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Fabry+Disease/2690\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"SNOMED CT\",\"id\":\"16652001\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500007\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6400\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"fabry-disease\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1292\",\"ref_field\":\"public_definition\"}"],"disease_mechanism":"Fabry disease is due to inactivating mutations in the X-linked GLA gene resulting in deficiency of the enzyme Alpha Galactosidase-A.","gard_id":"6400","alternate_names":["Alpha-galactosidase A deficiency","Anderson-Fabry disease","Angiokeratoma corporis diffusum","Angiokeratoma, diffuse","Ceramide trihexosidase deficiency","Ceramide trihexosidosis","Fabry syndrome","Fabry's disease","GLA deficiency","Hereditary dystopic lipidosis"],"keywords":[]}
